|Type/Product Area||Terms/Details (Date)|
|Amsterdam Molecular Therapeutics BV* (the Netherlands)||Digna Biotech SL* (Spain)||Licensing agreement to commercialize gene therapy products developed at the Center for the Study of Applied Medicine at the University of Navarra, Spain||AMT plans to start preclinical studies next year on the first program, an adeno-associated viral vector delivering insulin-like growth factor I for late-stage liver cirrhosis (11/27)|
|Arius Research Inc. (Canada; TSX:ARI)||Avid Bioservices Inc.*||Manufacturing supply and technology transfer agreement covering Arius' lead cancer stem cell antibody targeting an epitope of CD44 found in breast, colon and prostate cancers||Avid will begin manufacturing a supply of the drug for human trials, expected to start in 2008 (12/5)|
|Binex Co. Ltd.* (South Korea)||MaxCyte Inc.*||Sponsored research agreement to evaluate MaxCyte's GMP-compliant cell-loading technology for use in the closed-system manufacturing of Binex's cell-based cancer immunotherapies||The deal provides Binex an option to license MaxCyte's technology for clinical and commercial use in Korea (11/30)|
|BioAlliance Pharma SA (France; PARIS:BIO)||Immtech Pharmaceuticals Inc. (AMEX:IMM)||Exclusive licensing agreement granting BioAlliance European commercialization rights to pafuramidine maleate||Immtech will receive an initial license fee of $3M and stands to earn a further $13M in milestone payments if pafuramidine obtains regulatory approval in Europe; the U.S. company also will receive "significant" royalties and possibly two additional milestone payments linked to the value of sales (12/12**)|
|BioView Ltd.*||Transgenomic Inc. (OTC BB:TBIO)||Agreement to distribute BioView's family of Scanning and Analysis Workstations in selected Western European countries and Scandinavia||Transgenomic's European sales and support organization will market, sell and serve the instruments (11/6)|
|DOR BioPharma Inc. (OTC BB:DORB)||Orphan Australia Pty. Ltd.* (Australia)||Letter of intent for Orphan Australia to act as DOR's sponsor for administration of a Named Patient Access Program for orBec to gastro-intestinal graft-vs.-host disease patients in Australia, New Zealand and South Africa||OrBec is being investigated for use in bone marrow/stem cell transplantation patients (11/28)|
|Eden Biodesign Ltd.* (UK)||ImmunoBiology Ltd.* (UK)||Extended collaboration to develop ImmBio's influenza vaccine||The new contract covers a range of development and cGMP manufacturing services to produce material for ImmBio's Phase I trial (11/12)|
|Grant Life Sciences Inc. (OTC BB:GLIF)||Alphagenics Diaco Biotechnologies Srl* (Italy)||In-licensing agreement for the manufacturing and marketing rights to a molecular diagnostic test for human papilloma-viruses in Italy||Grant will hold exclusive rights in all other countries (11/13)|
|Innovex UK Ltd.* (UK; arm of Quintiles Trans-national Corp.)||PharmaMar SA (Spain subsidiary of Zeltia SA; LSE:ZEL)||Agreement to recruit, train and deploy a specialized oncology sales team in Western Europe to promote Yondelis, PharmaMar's treatment for soft-tissue sarcoma||PharmaMar will be responsible for marketing the drug, which was launched earlier this year in the UK and Germany (12/3)|
|Inspiration Bio-pharmaceuticals*||Cook Pharmica*||Agreement to conduct development work on a lead biologic therapy, an intravenous Factor IX product for hemophilia B||Financial terms were not disclosed (11/19)|
|Inverness Medical Innovations Inc. (AMEX:IMA)||Chemogen Inc.*||Agreement for the worldwide manufacture and distribution of tests for rapidly detecting Mycobacterium||Financial terms were not disclosed (11/8)|
|Kedrion SpA* (Italy)||ProMetic Bio-Therapeutics Inc.*||Agreement for multiple hyperimmunes, under which Kedrion will license tech nologies from ProMetic to enable hyperimmune manufacturing in Europe||The agreement is based on license fees, service fees and royalties to be paid to ProMetic (11/8)|
|Orthovita Inc. (VITA)||Allergan Inc. (NYSE:AGN)||Agreement to acquire raw material, equipment and a technology license from Allergan||Orthovita will pay $6.6M in cash; the deal relates primarily to the production of Orthovita's Vitagel Surgical Hemostat product, which combines bovine collagen and thrombin with the patient's auto-logous plasma (10/19)|
* Private companies are indicated with an asterisk.Unless otherwise noted, stock symbols listed are on the Nasdaq market.
ASX = Australian Stock Exchange; BE = Berlin Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.